Oppenheimer Sees 215% Upside in Viking Therapeutics as VK2735 Options Expand Beyond Near-Term Readouts

Wall Street stays bullish on VKTX as Oppenheimer sees expanded opportunities for VK2735 beyond near-term readouts and funding into 2028.